Loading
Life sciences · Journal article
Pharmaceuticals · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, circular RNAs, tRNA-derived fragments, PIWI-interacting RNAs, and small nucleolar RNAs, have been identified as crucial regulators of gene expression and key drivers of cancer progression. Natural products, owing to their structural diversity and multi-targeting capacity, represent a promising reservoir for anticancer drug discovery through the modulation of these ncRNA networks. This review provides a comprehensive overview of the regulatory roles of natural products on ncRNAs in cancer. Compared with previous reviews that focus on individual ncRNA classes or single natural product categories, this review provides an integrated framework linking ncRNA biology, natural product pharmacology, and therapeutic delivery in cancer. First, the biogenesis, classification, and molecular functions of major ncRNA classes are systematically described, and the dysregulation of each ncRNA class across various cancer types and their contributions to tumor pathogenesis are then discussed. Subsequently, the modulation of these ncRNA networks by representative natural products, including polyphenols, flavonoids, terpenoids, and alkaloids, to influence multiple hallmarks of tumor progression, encompassing cell proliferation, programmed cell death, metastatic dissemination, tumor microenvironment remodeling, and therapeutic resistance, is reviewed. The potential of ncRNAs as diagnostic, prognostic, and pharmacodynamic biomarkers in the context of natural product-based therapy is discussed, together with emerging nanoparticle-based delivery strategies for co-delivering natural products and ncRNA therapeutics; however, most of the evidence summarized here remains preclinical, and clinical translation will require rigorous pharmacological and clinical validation. Finally, we address current challenges and future perspectives for the clinical translation of natural product–ncRNA-based anticancer strategies.